Mechanism of Action & Potential Impact of Tislelizumab

This discussion explores how tislelizumab’s unique Fc-region engineering may influence its activity in gastric cancer, particularly in patients with peritoneal metastases. Tislelizumab is designed to minimize binding to Fc-gamma receptors on macrophages, a modification intended to reduce macrophage-mediated clearance of activated T cells and help support a sustained anti-tumor immune response. This mechanism is scientifically relevant in the peritoneal cavity, where macrophages are abundant and can contribute to an immunosuppressive microenvironment. By limiting interaction with these cells, tislelizumab may offer a theoretical advantage in this difficult-to-treat subgroup. While this rationale is grounded in mechanistic biology, clinical validation is still needed to determine the extent of benefit in patients with peritoneal metastases. This segment highlights the scientific foundation behind tislelizumab’s design and its potential implications for addressing unmet needs in advanced gastric cancer.